It is believed that reasons for these racial disparities may include socioeconomic factors, but the true causes are not fully understood. Some researchers believe that immunologic differences may also play a role.
The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Progressive multifocal leukoencephalopathy (PML) is caused by John Cunningham virus (JCV). A recently published study suggests that the number of cases of PML related to Tysabri (natalizumab) have been decreasing perhaps as a result of increased monitoring.